LUPKYNIS

Peak

voclosporin

NDAORALCAPSULEPriority Review
Approved
Jan 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2

Mechanism of Action

Calcineurin Inhibitors

Pharmacologic Class:

Calcineurin Inhibitor Immunosuppressant

Clinical Trials (2)

NCT07053891N/ARecruiting

LUPKYNIS Drug-use Results Survey

Started Sep 2025
400 enrolled
Lupus Nephritis
NCT05337124N/ACompleted

A Prospective Observational Registry of Patients Treated With LUPKYNIS® (Voclosporin) in the US

Started Apr 2022
229 enrolled
Lupus Nephritis

Loss of Exclusivity

LOE Date
Dec 7, 2037
143 months away
Patent Expiry
Dec 7, 2037
Exclusivity Expiry
Jan 22, 2026

Patent Records (3)

Patent #ExpiryTypeUse Code
7332472
Oct 17, 2027
SubstanceProduct
U-3056
10286036
Dec 7, 2037
U-3056
11622991
Dec 7, 2037
U-3056